China A-Shares Rally as UBS Forecasts 11% Earnings Growth in 2026; Zhipu AI Hits 1 Trillion HKD

The Quick Take

• China A-shares rose broadly June 22 with insurance sector leading gains as volumes increased
• UBS forecasts A-share earnings growth to accelerate from 3.9% in 2025 to 11% in 2026 — a bullish re-rating signal
• Zhipu AI (China largest LLM developer) valuation breaks 1 trillion HKD eve of its A-share listing debut

China's A-share market rose broadly on June 22 with major indices moving higher on expanded volume, led by the insurance sector, according to China News Service. The market movement coincided with a significant UBS Securities forecast: UBS China equity strategist Meng Lei published analysis projecting that earnings growth for all A-share listed companies will accelerate from 3.9% in 2025 to 11% in 2026 — a more than doubling of corporate profit growth that, if realised, would justify meaningful multiple expansion in Chinese equities. The insurance sector leadership aligns with the broader premium-revenue growth and investment return improvement narrative for Chinese insurers.

The rally's timing coincides with Zhipu AI — described by TMTPost as China's version of Anthropic — breaking through a 1 trillion Hong Kong dollar market capitalisation threshold on the eve of its A-share domestic listing. Zhipu AI is one of China's largest large language model developers, with strong academic roots from Tsinghua University and significant government and private backing. Its founder's public comparison to Elon Musk signals the company's ambition to compete at the frontier of global AI development. The pre-listing valuation milestone is significant for the Chinese AI sector: it implies institutional and strategic investors are pricing Chinese LLM developers at globally competitive valuations despite the technology access restrictions imposed by US export controls on advanced chips.

The forward signals for the A-share bullish thesis are: (1) Q2 2026 corporate earnings releases validating UBS's 11% growth forecast; (2) Chinese government stimulus measures, particularly any targeted sector support that could amplify insurance or financial sector returns; (3) Zhipu AI's post-listing trading performance, which will calibrate market appetite for Chinese AI listings broadly. The macro variable is the US-China technology trade relationship: any easing of chip export controls would accelerate Chinese AI development timelines and compress the valuation discount investors apply to Chinese AI names versus US counterparts.

Synthesized from 3 sources.